Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Breast Cancer - ER+, HER2-, PIK3CA Gene Mutation”

7 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 7 of 7 results

Large-scale testing (Phase 3)Study completedNCT03439046
What this trial is testing

Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 287
Post-approval studies (Phase 4)Study completedNCT05631795
What this trial is testing

Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment

Who this might be right for
Advanced Breast Cancer
Novartis Pharmaceuticals 40
Early research (Phase 1)Study completedNCT02260661
What this trial is testing

Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours

Who this might be right for
Advanced Solid MalignanciesBreast Cancer - ER+, HER2 -Breast Cancer - ER+, HER2-, PIK3CA Gene Mutation
AstraZeneca 20
Testing effectiveness (Phase 2)Study completedNCT04300790
What this trial is testing

Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients

Who this might be right for
Breast Cancer
MedSIR 69
Not applicableNot Yet RecruitingNCT07387861
What this trial is testing

PI3K Pathway Activation Markers in ER-Positive, HER2-Negative Breast Cancer: A Clinicopathologic Study

Who this might be right for
Breast Cancer - ER+, HER2-, PIK3CA Gene Mutation
Assiut University 70
Early research (Phase 1)Study completedNCT01226316
What this trial is testing

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

Who this might be right for
Advanced Solid MalignancySafety and TolerabilityPharmacokinetics+11 more
AstraZeneca 285
Not applicableLooking for participantsNCT06805812
What this trial is testing

Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study

Who this might be right for
Breast AdenocarcinomaBreast Cancer Stage IVBreast Cancer, Metastatic+38 more
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 3,500